Richiedi info sul prodotto
Estimated delivery: 1-3 business days
Information on returns and shipments
Payment methods
Tachifluactiv Influenza E Fredreddore is an Angelini medicine based on paracetamol and pseudoephedrine hydrochloride, indicated for the treatment of cold and flu symptoms.
Adults and adolescents over 12 years of age: 1 effervescent tablet, 2-3 times a day for no more than 5 days in adults and for no more than 3 days in adolescents. Dissolve the tablet in a glass of water and drink the resulting solution immediately.
Paediatric populationTachifluactiv Influenza E Cold is not recommended for children under 12 years of age (see section 4.3 “Contraindications”).
The risk of serious side effects is also increased when paracetamol is taken together with other antipyretic analgesics; Concomitant use of this type of medicine should therefore be avoided.
Patients should be advised not to take other medicines containing paracetamol at the same time due to the risk of serious liver damage in case of overdose (See section 4.9).
Alcoholic drinks should be avoided while taking this medicine because alcohol used concomitantly with paracetamol can cause liver damage (See section 4.5). Paracetamol should be administered with caution to patients with alcohol dependence (See section 4.5).
This medicine should be given with caution to patients being treated with other medicinal products that affect the liver (See section 4.5).
During therapy with oral anticoagulants, it is advisable to reduce the dose. The patient should be advised to consult a doctor if he/she is already taking oral anticoagulants. under treatment with other medicinal products.
Caution is advised if paracetamol is administered concomitantly with flucloxacillin due to the increased risk of high anion gap metabolic acidosis (Hagma), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism), as well as in those using maximum daily doses of paracetamol. Careful monitoring is recommended, including measurement of urinary 5-oxoproline.
In case of surgery, it is advisable to stop treatment a few days beforehand, because the risk of hypertensive crisis is high. increased if halogenated anaesthetics are used (See section 4.5).
During treatment with Tachifluactiv Influenza E Cold, before taking any other medicine, check that it does not contain paracetamol, since serious adverse reactions may occur if this active ingredient is taken in high doses. Tachifluactiv Influenza E Cold should be used with caution in patients with:
Severe skin reactions such as acute generalized exanthematous pustulosis (Agep) may occur with products containing pseudoephedrine. This acute pustular eruption may occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules arising from a widespread edematous erythema and located mainly in the skin folds, trunk, and upper limbs. Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema or numerous small pustules are observed, the administration of Tachifluactiv Influenza E Cold should be discontinued and appropriate measures taken if necessary.
Some cases of ischemic colitis have been reported with medicinal products containing pseudoephedrine. The use of pseudoephedrine should be discontinued and it is recommended to consult a doctor if abdominal pain, rectal bleeding or other symptoms of ischemic colitis suddenly appear.
Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or reduction in visual acuity occurs, for example in the case of scotoma.
For those who participate in sports: the use of this medicine may cause positive anti-doping tests.
Patients should consult their doctor if:
Simethicone emulsion also contains: Benzoic acid: This medicine contains 0.06 mg of benzoic acid per tablet equivalent to 0.06 mg/3 g.
Adverse events are tabulated below by class and frequency. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, <1/100); rare (≥ 1/10,000, < 1/1,000); very rare (<1/10,000), or not known (frequency cannot be estimated from the available data).
Disease ClassFrequencyUndesirable EffectsBlood and lymphatic system disordersVery rarethrombocytopenia, agranulocytosis, leukopenia, pancytopeniaImmune system disordersRarehypersensitivity, angioedemaNot knownanaphylactic reactions, Stevens-Johnson syndrome, toxic epidermal necrolysisPsychiatric disordersRarenervousness, insomnia, anxiety, agitation, hallucinations (reported rarely, particularly in children)Symptoms nervous systemRaredizziness, headache, tremorEye disordersNot knownischemic optic neuropathyCardiac disordersRaretachycardia, palpitationsVascular disordersRarehypertensionGastrointestinal disordersRarevomiting, dryness mouth, nauseaNot knownischemic colitisHepatobiliary disordersRareincreased liver enzymesSkin and subcutaneous tissue disordersRarerash, erythema, urticaria, pruritusVery raresevere skin reactionsNot knownsevere skin reactions, including acute generalized exanthematous pustulosis (Agep)Renal and urinary disordersRareurinary retention, especially in patients with prostatic hypertrophyThe following side effects have also been reported: sweating, thirst, chest pain, difficulty breathing. urination, muscle weakness, mydriasis, gastric problems, ventricular arrhythmias, erythema multiforme, laryngeal edema, anaphylactic shock, anemia, liver function abnormalities, hepatitis, acute renal failure, interstitial nephritis, hematuria, anuria.
Reporting of suspected adverse reactionsReporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are encouraged to keep informed of any potential adverse reactions they may encounter. You are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.
In adults, the maximum daily dose of paracetamol is 4 g; above this limit there is a risk of dose-dependent hepatotoxicity. In case of acute overdose, paracetamol can exert a hepatotoxic effect or even cause liver necrosis. Paracetamol overdose, including high total dose levels achieved over a prolonged period, can cause nephropathy with irreversible liver failure. Patients should be advised not to take other medicines containing paracetamol at the same time. There is a risk of poisoning, particularly in the elderly, children, patients with liver disease, chronic alcoholism, chronic malnutrition, and patients treated with enzyme inducers. Paracetamol overdose can cause liver failure, encephalopathy, coma, and death. Symptoms of Paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, and anorexia. Abdominal pain may be the first indication of liver damage, which is usually not apparent for 24–48 hours and can sometimes be delayed up to 4–6 days after ingestion. Liver damage generally reaches a maximum 72–96 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrhythmias and Pancreatitis have been reported. Immediate treatment is essential in the management of paracetamol overdose. Early administration of N-acetylcysteine IV or oral as an paracetamol antidote, possibly gastric lavage and/or administration of oral methionine, may be beneficial for up to at least 48 hours after overdose. Administration of activated charcoal and active monitoring of respiration and circulation may be helpful. In cases of convulsions, diazepam may be administered.
Pseudoephedrine hydrochlorideDue to the nature of this sympathomimetic agent, overdose leads to stimulation of the central nervous system. Symptoms are irritability, restlessness, excitation, tremor, convulsions, palpitations, hypertension, and difficulty in urination. However, overall the data indicate that pseudoephedrine is a safe and effective treatment for convulsions. Diazepam is well tolerated and safe when used as a nasal decongestant at the recommended dose, and does not produce irreversible toxicity even with a significant overdose. In the event of a very serious overdose, interventions should be made to control seizures; diazepam can be used as an anticonvulsant and sedative. Measures should be taken to support breathing. Beta-blockers may be used to limit possible side effects such as tachycardia, arrhythmia, and hypokalemia. If necessary, gastric lavage may be attempted to remove the drug. To accelerate the elimination of pseudoephedrine, dialysis or acid diuresis may be used. Bladder catheterization may be necessary.
Epidemiological studies in pregnancy have shown no negative effects due to paracetamol used at the recommended dosage. Reproduction studies involving oral administration have shown no signs of malformations or fetotoxicity (see section 5.3). Under normal conditions of use, paracetamol can be administered during pregnancy after considering the risk/benefit ratio. There are limited data on the use of pseudoephedrine in pregnant women. Vasoconstriction of uterine vessels and reduced uterine blood flow associated with the use of pseudoephedrine may cause fetal hypoxia. The use of pseudoephedrine is contraindicated during pregnancy.
BreastfeedingBoth paracetamol and pseudoephedrine pass into breast milk in small amounts. Since There are no data available on the association of the two substances; the medicine should be avoided during breastfeeding.
FertilityThe effects of Tachifluactiv Influenza E Freddore on fertility have not been specifically studied. Preclinical studies with paracetamol do not indicate any particular risks for fertility at therapeutically relevant doses. There are insufficient reproductive toxicology studies with pseudoephedrine.
10 Tablets
This product has been on sale since 08/01/2026
In the last 30 days, the product's lowest price was 7,17 €
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
